**Name of Journal:** *World Journal of Hepatology*

**Manuscript No:** 76705

**Manuscript Type:** ORIGINAL ARTICLE

***Basic Study***

**Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease**

Li XY *et al*. Lipid-laden hepatocytes affect macrophages

Xiao-Yun Li, Pei-Xuan Ji, Xi-Xi Ni, Yu-Xin Chen, Li Sheng, Min Lian, Can-Jie Guo, Jing Hua

**Xiao-Yun Li, Pei-Xuan Ji, Xi-Xi Ni, Yu-Xin Chen, Li Sheng, Min Lian, Can-Jie Guo, Jing Hua,** Department of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiaotong University School of Medicine), Shanghai 200127, China

**Author contributions:**Li XY, Ji PX, and Ni XX contributed equally to this work; Hua J designed the research; Li XY, Ji PX and Ni XX performed the research; Chen YX, Sheng L, Lian M and Guo CJ analyzed the data; Li XY and Hua J wrote the paper.

**Supported by** the National Natural Science Foundation of China, No. 81770572.

**Corresponding author: Jing Hua, MD, PhD, Professor,** Department of Gastroenterology and Hepatology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, NHC Key Laboratory of Digestive Diseases (Renji Hospital, Shanghai Jiaotong University School of Medicine), No. 160 Pujian Road, Shanghai 200127, China. hua\_jing88@163.com

**Received:** March 26, 2022

**Revised:** May 9, 2022

**Accepted:** June 22, 2022

**Published online:** July 27, 2022

**Abstract**

BACKGROUND

Lipid metabolism disorder and inflammatory-immune activation are vital triggers in the pathogenesis of nonalcoholic fatty liver disease (NAFLD). Various studies have shown that PPAR-γ exerts potent anti-inflammatory and immunomodulatory properties. However, little is known about the regulation of PPAR-γ activity in modulating cell crosstalk in NAFLD.

AIM

To investigate whether the regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation.

METHODS

Primary hepatocytes were isolated from wild-type C57BL6/J mice or hepatocyte-specific PPAR-γ knockout mice and incubated with free fatty acids (FFAs). Macrophages were incubated with conditioned medium (CM) from lipid-laden hepatocytes with or without a PPAR-γ agonist. Wild-type C57BL/6J mice were fed a high-fat (HF) diet and administered rosiglitazone.

RESULTS

Primary hepatocytes exhibited significant lipid deposition and increased ROS production after incubation with FFAs. CM from lipid-laden hepatocytes promoted macrophage polarization to the M1 type and activation of the TLR4/NF-κB pathway. A PPAR-γ agonist ameliorated oxidative stress and NLRP3 inflammasome activation in lipid-laden hepatocytes and subsequently prevented M1 macrophage polarization. Hepatocyte-specific PPAR-γ deficiency aggravated oxidative stress and NLRP3 inflammasome activation in lipid-laden hepatocytes, which further promoted M1 macrophage polarization. Rosiglitazone administration improved oxidative stress and NLRP3 inflammasome activation in HF diet-induced NAFLD mice in vivo.

CONCLUSION

Upregulation of PPAR-γ activity in hepatocytes alleviated NAFLD by modulating the crosstalk between hepatocytes and macrophages *via* the reactive oxygen species-NLRP3-IL-1β pathway.

**Key Words:** Nonalcoholic fatty liver disease; Hepatocyte; Macrophage polarization; PPAR-γ; NLRP3; Oxidative stress

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation**：Li XY, Ji PX, Ni XX, Chen YX, Sheng L, Lian M, Guo CJ, Hua J. Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation in nonalcoholic fatty liver disease. *World J Hepatol* 2022; 14(7): 1365-1381 **URL**: https://www.wjgnet.com/1948-5182/full/v14/i7/1365.htm

**DOI**: https://dx.doi.org/10.4254/wjh.v14.i7. 1365

**Core Tip:** Nonalcoholic fatty liver disease (NAFLD) is currently one of the most endemic chronic liver diseases worldwide. We aimed to investigate whether the regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and to explore the underlying mechanism. Our study revealed that lipid-laden hepatocytes skewed macrophage polarization to the M1 phenotype. Regulation of PPAR-γ activity alleviates NAFLD by modulating the crosstalk between hepatocytes and macrophages *via* the reactive oxygen species-NLRP3-IL-1β signaling pathway. Strategies that manipulate PPAR-γ activity to regulate cell crosstalk will be beneficial for treating NAFLD.

**INTRODUCTION**

Nonalcoholic fatty liver disease (NAFLD) is currently one of the most common liver diseases, with a high morbidity presently exceeding 25% worldwide[1,2]. Manifesting from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) and even to cirrhosis and hepatocellular carcinoma, NAFLD has already posed heavy public and financial burdens worldwide[3]. Given the lack of effective medications for treatment, there is a need to deeply explore the pathogenesis of NAFLD and to look for potential therapeutic targets for alleviating NAFLD[4].

Lipid metabolism disorder and inflammatory immune activation are two main triggers in the pathogenesis of NAFLD[5]. The widely accepted “two-hit theory” suggests that excess free fatty acids (FFAs) act as the first hit, causing abnormal lipid accumulation and insulin resistance and increasing the susceptibility of the liver to inflammatory damage[5,6]. Based on the first hit, the second hit involves activation of immune cells and oxidative metabolite production, leading to oxidative stress and an inflammatory response[7-9]. Hence, the accumulation of lipotoxic agents in hepatocytes is key to the onset and progression of NAFLD. Lipotoxicity can directly induce endoplasmic reticulum stress and pyroptosis in steatotic hepatocytes[10,11]. Among the many factors that trigger the progression of NAFLD to NASH, activation of immune cells plays a prominent and indispensable role[12].

Activation of macrophages, including hepatic resident Kupffer cells and peripherally recruited monocytes, plays an important role in the progression of NAFLD[12,13]. It is now widely considered that macrophages can be classified into two types: the classically activated M1 phenotype and the alternatively activated M2 phenotype. M1 phenotype macrophages are mainly induced by interferon-γ and lipopolysaccharide and secrete proinflammatory factors (IL-1, 6, 12, 23, CXCL 10, NO, peroxides, *etc.)*, which participate in the Th1 immune response and exert proinflammatory, bactericidal and antitumor effects. M2 macrophages are mainly induced by IL-4 and IL-10 and participate in the Th2 immune response with anti-inflammatory and tissue remodeling effects[14,15]. Under normal conditions, macrophages in the liver predominantly exhibit an M2 phenotype[16]. However, in NAFLD mice induced by a high-fat diet, the number of macrophages increases dramatically, and the polarity of macrophages appears to shift toward the M1 type[17]. These M1 phenotype macrophages contribute to the progression and prolongation of liver inflammation[13]. However, there is no certainty as to what exactly drives the activation of macrophages. Recent studies have revealed that various factors, including high levels of free fatty acids and the gut microbiota, may lead to macrophage activation[18,19]. Furthermore, the crosstalk or interaction between parenchymal and nonparenchymal cells in the liver may reciprocally regulate macrophage phenotype or function.

PPAR-γ is a ligand-activated nuclear transcription receptor that mainly participates in adipocyte differentiation, lipogenesis, and insulin resistance[20]. Recently, much attention has been focused on the immunomodulatory and anti-inflammatory properties of PPAR-γ[21]. It has been demonstrated that activation of PPAR-γ synergistically upregulates the NRF2/HO-1 signaling pathway, thereby ameliorating methotrexate-induced hepatotoxicity[22]. Our previous study demonstrated that regulation of PPAR-γ activity in macrophages and HSCs could modulate their activation and alleviate the development of NAFLD/NASH[17,23]. Most previous studies have focused on the anti-inflammatory properties of PPAR-γ in nonparenchymal cells, such as macrophages and HSCs, in NASH; thus, the role of PPAR-γ in hepatocytes and the interaction between hepatocytes and macrophages remain to be explored.

In the current study, we aimed to investigate whether the regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and explore the underlying mechanism. We found that upregulation of PPAR-γ activity could alleviate NAFLD through modulation of the crosstalk between hepatocytes and macrophages *via* the ROS-NLRP3-IL-1β signaling pathway.

**MATERIALS AND METHODS**

***Primary hepatocyte isolation and treatment***

Primary hepatocytes were isolated from wild-type C57BL/6 mice or hepatocyte-specific PPAR-γ knockout mice *via* two-step collagenase in situ perfusion of the liver[24] and then cultured in DMEM containing 10% FBS (Gibco, Waltham, MA, United States) with 100 U/mL penicillin G and 100 U/mL streptomycin sulfate at 37 °C with 5% CO2 on collagen I-coated plates. The viability of primary hepatocytes was assessed using a trypan blue exclusion test and was greater than 95%. Mixed free fatty acids (FFAs) with a final concentration of 1 mmol/L were prepared with palmitic acid (PA, 0.66 mmol/L, Sigma Aldrich) and oleic acid (OA, 0.33 mmol/L, Sigma Aldrich)[25]. After overnight culture, primary hepatocytes were treated with FFAs for 24 h to induce a cell model of NAFLD in vitro. In some experiments, primary hepatocytes were pretreated with the PPAR-γ agonist GW1929 (20 μmol/L, Sigma Aldrich) for 3 h, followed by incubation with FFAs for 6 h or 24 h. Cell lysates were collected for RT–PCR and western blot analyses.

***RAW264.7 macrophage culture and treatment***

RAW264.7 macrophages were purchased from the Cell Bank of the Chinese Academy of Sciences and cultured in DMEM containing 10% fetal bovine serum with 100 U/mL penicillin G and 100 U/mL streptomycin sulfate at 37 °C with 5% CO2. All experimental interventions were conducted on the third passage of cells.

***Primary hepatocyte and RAW264.7 macrophage conditional coculture system***

As mentioned above, primary hepatocytes were incubated with FFAs or with GW1929 for 3 h followed by FFAs. Then, the cell culture supernatants were collected, centrifuged, and filtered to remove impurities. RAW264.7 macrophages were incubated with different types of conditioned medium (CM) from primary hepatocytes to establish conditional coculture systems for 6 h or 24 h, which were called CM-NC, CM-FFA, and CM-GW1929+FFA.

***Animal experiments***

The animal protocol was designed to minimize pain or discomfort to the animals. Ppargfl/fl mice and Alb-cre mice on the C57BL6/J background were purchased from GemPharmatech (Nanjing, China) to breed and obtain hepatocyte-specific PPAR-γ knockout (PPAR-γ▲hep) male mice (Supplementary Figure 2). Wild-type C57BL/6 male mice (aged 6-8 weeks) were obtained from the Experimental Animal Center (Renji Hospital, Shanghai Jiao Tong University). Wild-type mice were fed either a normal control (NC) diet (15% kilocalories from fat, *n* = 10) or a high-fat (HF) diet (60% kilocalories from fat, *n* = 10) for 16 weeks. For the rosiglitazone intervention experiment, mice received rosiglitazone (30 mg/kg/day, Sigma Aldrich) by oral gavage once daily for 28 consecutive days after 12 weeks of HF diet feeding (*n* = 10). All animal experiments fulfilled the Shanghai Jiao Tong University criteria for the humane treatment of laboratory animals and were approved by the Renji Hospital Animal Care and Use Committee (Permit number: RJ2018-0930).

***Oil Red O staining***

Free fatty acid-treated hepatocytes were fixed with 4% paraformaldehyde for 1 h and then stained with 5 mg/mL Oil Red O (Sigma Aldrich) for 60 min to examine lipid accumulation.

***Assay of lipid contents, IL-1β concentration and oxidative stress markers***

The cell culture supernatant of primary hepatocytes was collected for further analysis. Triglyceride (TG) and total cholesterol (T-CHO) were measured using a triglyceride assay kit and a total cholesterol assay kit, respectively (Nanjing Jiancheng Bioengineering Institute, China). The IL-1β concentration was measured using an IL-1β ELISA kit (Lianke Biotechnology Company, China). Plasma from mice was centrifuged, separated and stored at -80 °C for further analysis. Plasma levels of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione (GSH) were measured using MDA, SOD and GSH assay kits, respectively (Nanjing Jiancheng Bioengineering Institute, China). The plasma level of reactive oxygen species (ROS) was measured using an ROS ELISA kit (Nanjing JiaBeiSen Biotechnology, China). ROS generation in the cell culture supernatant was assayed using a DCFH-DA fluorescent probe kit (Beyotime Biotechnology, China). Total protein was extracted from mouse liver tissues. Caspase-1 activity in liver tissues was assessed with a Caspase-1 activity assay kit (BioVision, Milpitas, CA, United States). All procedures were performed according to the manufacturers’ instructions.

***Total RNA isolation and real-time PCR***

Total RNA was extracted from mouse liver tissues, RAW264.7 macrophages and primary hepatocytes using TRIzol reagent (TaKaRa, Kusatsu, Japan). Complementary DNA was generated from 1 µg of RNA using a cDNA synthesis kit (Nanjing Vazyme Biotech, China). For real-time PCR, 10 ng of template was added to a 10-μL reaction system containing each primer and SYBR Green PCR Master Mix (TaKaRa, Kusatsu, Japan). The PCR thermocycling parameters were 95 °C for 30 s, followed by 40 cycles of 95 °C for 5 s and 60 °C for 30 s, performed with an ABI Prism 7300 system (Applied Biosystems, Foster City, CA). All reactions were performed in triplicate. The expression levels of target genes were quantified using the double-delta method (2-ΔΔCt). The murine primers (provided by Sangon Biotech Co., Shanghai, China) are shown in Table 1.

***Western blotting***

Total proteins extracted from mouse liver tissues, RAW264.7 macrophages and primary hepatocytes were assessed using a Pierce BCA protein assay kit (Thermo Fisher Scientific). The proteins were separated by SDS–PAGE (Epizyme Biotech), transferred to polyvinylidenedifluoride membranes (Bio-Rad, Hercules, CA) and incubated with primary antibody in TBST containing 5% (wt/vol) BSA at 4 °C overnight. The blots were then incubated with HRP-conjugated secondary antibody (1:10000, KangChen Biotech, Shanghai, China) at room temperature for 1 h. Immunoreactive bands were detected with an ECL chemiluminescence kit (Thermo Scientific Pierce, Waltham, MA). The density of the bands on the immunoblots was measured using ImageJ software (National Institutes of Health) and was normalized to that of glyceraldehyde 3-phosphate dehydrogenase (1:10000, KangChen Biotech, Shanghai, China) or β-actin (1:5000, Cell Signaling Technology). In this study, the total expression levels of TLR4, IκBα, p-IκBα, NF-κB and p-NF-κB (1:1000, all from Cell Signaling Technology) in macrophages were measured and normalized to the β-actin (1:5000, Cell Signaling Technology) expression level. The total expression levels of NLRP3, IL-1β, Caspase-1, Nrf2, Keap1 and HO-1 (1:1000, all from Cell Signaling Technology) in hepatocytes were measured and normalized to the GAPDH (1:10000, KangChen Biotech, Shanghai, China) expression level.

***Statistical analysis***

All statistical analyses were carried out with GraphPad Prism v7.03 software (GraphPad, La Jolla, CA, United States). All the data are expressed as the mean ± SE of the mean. Statistical differences among multiple groups were determined by one- or two-way analysis of variance. Differences between two groups were analyzed using Student’s *t* test. A *P* value < 0.05 was considered statistically significant.

**RESULTS**

***Lipid-laden primary hepatocytes have direct effects on M1/M2 macrophage polarization and inflammation***

Because of their high plasticity and heterogeneity, macrophages can be skewed into the M1 phenotype or M2 phenotype under different microenvironments[26]. However, whether lipid-laden hepatocytes can affect macrophage polarization is uncertain. Here, we isolated primary hepatocytes and incubated them with FFAs. After 24 h of culture, most primary hepatocytes adhered to the plate and exhibited centered dual nuclei and a polyhedral shape under the microscope, indicating that the primary hepatocytes were in good condition (Figure 1A). Moreover, the hepatocytes displayed excess lipid accumulation after incubation with FFAs, as shown by Oil Red O staining (Figure 1B). At the same time, the TG and T-CHO contents generated in hepatocytes were significantly increased (Figure 1C). The mRNA expression levels of the lipid synthesis genes Fasn and Srebp1c were upregulated, and the mRNA expression levels of the lipid decomposition genes Acox1 and Cpt1a were downregulated (Figure 1D). These results suggested that the NAFLD hepatocyte model was successfully established. Next, a supernatant transfer experiment between lipid-laden hepatocytes and macrophages was established. We found that CM from FFA-treated hepatocytes induced M1-polarized macrophages with significant upregulation of all M1 markers, including Nos2, Tnf and Il-6, and partial downregulation of M2 markers, such as Il-10 (Figure 1E). In addition, the NF-κB signaling pathway in macrophages was activated by CM-FFA, as demonstrated by significant increases in the protein expression levels of TLR4, p-NF-κB and p-IκBα (Figure 1F). These results demonstrate that lipid-laden hepatocytes exert direct roles in M1 macrophage polarization and inflammation.

***Lipid-laden hepatocytes induce macrophage M1 polarization and inflammation via IL-1β signaling***

Lipid-laden hepatocytes promoted M1 macrophage polarization and inflammation; however, the possible pathways of signal exchange between the primary hepatocytes and macrophages were unclear. We found that incubation with FFAs obviously increased the mRNA and protein expression levels of the inflammatory factor IL-1β in hepatocytes (Figure 2A and B). Similarly, lipid-laden hepatocytes secreted a high level of IL-1β into the cell culture supernatant (Figure 2C). To further investigate whether IL-1β participates in the signaling between hepatocytes and macrophages, we pretreated macrophages with an interleukin-1 receptor antagonist (IL-1Ra) to block IL-1β receptors. Then, a supernatant transfer experiment between lipid-laden hepatocytes and macrophages was conducted. The results showed that IL-1β expression in macrophages was significantly decreased with IL-1Ra pretreatment (Figure 2D). As expected, we found that inhibition of IL-1β signaling with IL-1Ra significantly prevented macrophage M1 polarization induced by CM-FFAs, as shown by the downregulation of M1-type markers and the upregulation of M2-type markers (Figure 2E). Simultaneously, IL-1Ra suppressed the protein expression levels of TLR4, p-NF-κB and p-IκBα in macrophages induced by CM-FFA (Figure 2F). These results indicate that NAFLD hepatocytes induce M1 macrophage polarization and inflammatory signal activation *via* IL-1β signaling.

***Upregulation of PPAR-γ activity ameliorates oxidative stress and NLRP3 inflammasome activation in lipid-laden hepatocytes***

PPAR-γ is a nuclear receptor that is firmly involved in lipid metabolism and the inflammatory-immune response[27]. To further explore the role and properties of PPAR-γ in lipid-laden primary hepatocytes, the PPAR-γ agonist GW1929 was added to the hepatocyte culture system for 3 h before incubation with FFAs. The results showed that GW1929 administration significantly decreased the ROS content and IL-1β secretion level in hepatocytes treated with FFAs (Figure 3A and B). In addition, GW1929 significantly downregulated both the mRNA and protein expression levels of NLRP3 inflammasome-related genes, including Nlrp3, Caspase-1 and IL-1β, in lipid-laden hepatocytes (Figure 3C and D). Furthermore, GW1929 markedly reduced the mRNA and protein expression levels of the oxidative injury marker Keap1 but enhanced the mRNA and protein expression levels of the antioxidant-related genes Nrf2 and Ho-1 (Fig. 3E, 3F). These results indicate that upregulation of PPAR-γ activity in NAFLD hepatocytes can ameliorate oxidative stress and NLRP3-IL-1β pathway activation.

***Hepatocyte-specific PPAR-γ knockout aggravates oxidative stress and NLRP3 inflammasome activation in lipid-laden hepatocytes***

To further confirm the anti-inflammatory and antioxidant effects of PPAR-γ on lipid-laden hepatocytes, we isolated primary hepatocytes from hepatocyte-specific PPAR-γ knockout mice and treated them with FFAs in vitro. The mRNA expression level of Ppar-γ in primary hepatocytes from hepatocyte-specific PPAR-γ knockout mice was fully knocked out (Figure 4A). As expected, the loss of PPAR-γ in hepatocytes enhanced IL-1β secretion and ROS generation after incubation with FFAs (Figure 4B and C). In addition, PPAR-γ deficiency in lipid-laden hepatocytes increased the mRNA and protein expression levels of the Nlrp3, Caspase-1 and IL-1β genes (Figure 4D and E). Furthermore, PPAR-γ deficiency markedly increased the mRNA and protein expression levels of Keap1 but decreased the mRNA and protein expression levels of Nrf2 and Ho-1 (Figure 4F and G). These results further confirm that PPAR-γ exerts a protective effect against lipid peroxidation and inflammation in lipid-laden hepatocytes.

***Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation***

Next, we further explored whether regulation of PPAR-γ activity in lipid-laden hepatocytes would subsequently affect macrophage polarization shifts and inflammation. Macrophages were incubated with CM derived from hepatocytes that were pretreated with GW1929 or FFAs alone or with CM from PPAR-γ-deficient hepatocytes treated with FFAs. Interestingly, the increase in M1 marker expression was significantly downregulated and the expression levels of the M2 markers Arg1 and Il-10 were markedly upregulated in macrophages incubated with CM from lipid-laden hepatocytes that were pretreated with GW1929 (CM-GW1929+FFA) compared with the CM-FFA group (Figure 5A). In addition, the protein expression levels of TLR4, p-NF-κB and p-IκBα were significantly decreased in macrophages from the CM-GW1929+FFA group (Figure 5B). In contrast, depletion of PPAR-γ in lipid-laden hepatocytes significantly upregulated the mRNA expression levels of all M1 markers but decreased the mRNA expression levels of Arg1 and Mrc2 in macrophages (Figure 5C). Furthermore, depletion of PPAR-γ in lipid-laden hepatocytes further promoted activation of the TLR4/NF-κB signaling pathway in macrophages (Figure 5D). These results illustrate that regulation of PPAR-γ activity in NAFLD hepatocytes can modulate macrophage polarization and inflammation.

***Rosiglitazone improved NLRP3 inflammasome activation and oxidative stress in high-fat diet-induced NAFLD mice***

Our in vitro experiments demonstrated that PPAR-γ exerts anti-inflammatory and antioxidant effects in lipid-laden hepatocytes, which can further affect macrophage polarization and inflammation. Next, we further explored whether these effects also occur in vivo. Our previous studies showed that rosiglitazone administration improves hepatic steatosis and Kupffer cell activation in high-fat diet-induced NAFLD mice. Here, we found that rosiglitazone significantly decreased the mRNA expression levels of the Nlrp3, Caspase-1 and Il-1β genes in bulk cells from the livers of high-fat diet-induced NAFLD mice (Figure 6A). Furthermore, rosiglitazone markedly downregulated the mRNA expression level of Keap1 but increased the mRNA expression levels of Ppar-γ, Nrf2 and Ho-1 (Figure 6B). The IL-1β level in plasma and the Caspase-1 activity in the liver both declined after rosiglitazone administration (Figure 6C and D), while the SOD activity and GSH content were significantly enhanced in rosiglitazone-treated mouse plasma (Figure 6E). In contrast, the levels of oxidative injury metabolites, such as ROS and MDA, in plasma were decreased after rosiglitazone intervention (Figure 6F). Therefore, we concluded that rosiglitazone not only alleviated hepatic steatosis and Kupffer cell activation but also improved NLRP3 inflammasome activation and oxidative stress in HF diet-fed NAFLD mice.

**DISCUSSION**

Lipid metabolism disorder is a critical initiator of the inflammatory response and immune activation in NAFLD[10]. How lipids lead to innate immune activation is poorly understood. Here, we demonstrated that lipid-laden hepatocytes can transmit inflammatory signals to macrophages through the release of IL-1β, directly inducing M1 macrophage polarization and inflammatory activation. Regulation of PPAR-γ activity in lipid-laden hepatocytes further affected macrophage polarization and inflammation. In addition, an in vivo study showed that a PPAR-γ agonist improved NLRP3 inflammasome activation and oxidative stress in high-fat diet-induced NAFLD mice, expanding our understanding of the underlying mechanisms of PPAR-γ in NAFLD.

Macrophage activation is considered to be a prominent hallmark of NASH[28]. The polarization of macrophages is firmly related to the inflammatory state. Previous studies have suggested that macrophages are more likely to transform from the M1 to the M2 phenotype if activation of the NF-κB signaling pathway is inhibited[15]. TLR4 deficiency directly alters the polarization of adipose tissue macrophages toward alternative activation[29]. Upon activation, macrophages not only release inflammatory cytokines and chemokines but also regulate the status or function of surrounding cells[13,30]. Recent studies have demonstrated that selective depletion of Kupffer cells reduced liver steatosis and monocyte infiltration in NASH[31-33]. Our previous study confirmed that macrophages/Kupffer cells polarized by fatty acids can regulate lipid metabolism in hepatocytes[30]. This result suggests a potential interaction between macrophages and hepatocytes in NAFLD. In the current study, our results revealed that lipid-laden hepatocytes directly induced macrophage M1 polarization and TLR4/NF-κB pathway activation. Through an in-depth study, we found that IL-1β secreted by lipid-laden hepatocytes mediates the communication between hepatocytes and macrophages. Interestingly, we confirmed that when macrophages were blocked with an IL-1β receptor inhibitor, M1 macrophage polarization induced by lipid-laden hepatocytes was weakened. Furthermore, we verified that residual fatty acids in hepatocyte supernatant alone were not sufficient to induce macrophages toward M1 polarization (Supplementary Figure 1).

PPAR-γ is a ligand-activated nuclear receptor with potent anti-inflammatory properties and is involved in the regulation of immune and inflammatory responses[34]. A recent study demonstrated that modulation of PPAR-γ activity attenuated HFD-induced NAFLD by regulating lipid metabolism and oxidative stress in hepatocytes *via* Nrf2 activation[35]. Due to the low expression of PPAR-γ in hepatocytes, the role of PPAR-γ in hepatocytes is not fully understood[36]. In the current study, we found that ROS generation and IL-1β secretion in lipid-laden hepatocytes were significantly reduced when cells were pretreated with the PPAR-γ agonist GW1929. Recently, a study reported that PPAR-γ exerted an anti-inflammatory effect by suppressing NLRP3 inflammasome activation in macrophages[37]. Here, we revealed that a PPAR-γ agonist exerted an anti-inflammatory effect by inhibiting NLRP3 inflammasome activation in lipid-laden hepatocytes. In contrast, PPAR-γ deficiency in hepatocytes enhanced ROS generation, NLRP3 inflammasome activation, and IL-1β secretion after FFA treatment in vitro.

Interestingly, we further found that upregulation of PPAR-γ activity in lipid-laden hepatocytes subsequently reversed macrophage M1 polarization and reduced activation of the TLR4/NF-κB pathway. Conversely, PPAR-γ depletion in lipid-laden hepatocytes exacerbated macrophage M1 polarization and TLR4/NF-κB pathway activation. This result suggests that the regulation of PPAR-γ activity in hepatocytes plays an important role in the interaction between lipid-laden hepatocytes and macrophages. Our previous study revealed that rosiglitazone, a PPAR-γ agonist, significantly alleviated hepatic lipid deposition and Kupffer cell activation in HFD-induced NAFLD mice[17]. In the present study, our results clearly demonstrated that rosiglitazone mitigated NLRP3 inflammasome activation and oxidative stress in HFD-induced NAFLD mice.

A recent study showed that hepatocyte-specific PPAR-γ disruption reduced hepatic steatosis but increased hepatic neutrophil infiltration after HFD feeding plus binge ethanol[38]. PPAR-γ deletion in hepatocytes highly augmented PA- or TNF-α-induced production of Cxcl1. This result indicates that PPAR-γ activation in hepatocytes exerted an anti-inflammatory effect, which was consistent with our findings. Another study found that hepatocyte-specific loss of PPAR-γ reduced the progression of high fat, cholesterol, and fructose (HFCF)-induced NASH in mice[39]. These findings seem to suggest that hepatocyte PPAR-γ contribute to the development of inflammation and fibrosis in NASH. However, the hepatocyte-specific loss of PPAR-γ did not reduce hepatic steatosis in HFCF- or MCD-induced NASH[39]. These contradictory experimental results may be due to the use of different animal models in the studies. In the current study, lipid-laden hepatocytes were established by incubation excess FFAs in vitro. The classical lipogenic property of PPAR-γ is significantly involved in this condition[40]. In addition, we further found that PPAR-γ activation exerted obvious antioxidant and anti-inflammatory effects in lipid-laden hepatocytes. We assumed that FFA overload directly led to lipotoxicity in hepatocytes, which contributed to lipid peroxidation. Thus, PPAR-γ was upregulated and exerted antioxidant effects against ROS to mitigate cell injury and downstream inflammatory events. Therefore, the role of PPAR-γ in hepatocytes is firmly related to different models, diet patterns and cellular stimulations. PPAR-γ is a complex nuclear receptor with specific dominant properties in various disease courses.

**CONCLUSION**

In conclusion, our study revealed that lipid-laden hepatocytes significantly skewed macrophage polarization to the M1 phenotype. Upregulation of PPAR-γ activity in lipid-laden hepatocytes improved macrophage M1 polarization and inflammation by attenuating hepatocyte oxidative stress and NLRP3 inflammasome activation. Strategies that target the regulation of PPAR-γ activity to modulate cell crosstalk will be beneficial for treating NAFLD.

**ARTICLE HIGHLIGHTS**

***Research background***

Lipid metabolism disorder and inflammatory-immune activation are two vital triggers in nonalcoholic fatty liver disease (NAFLD). Little is known about the regulation of PPAR-γ activity in modulating cell crosstalk in NAFLD.

***Research motivation***

The role of PPAR-γ in hepatocytes and in the interaction between hepatocytes and macrophages in NAFLD remain unknown.

***Research objectives***

To investigate whether the regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation and explore the potential mechanisms.

***Research methods***

Primary hepatocytes were isolated from wild-type C57BL6/J mice or hepatocyte-specific PPAR-γ knockout mice and incubated with free fatty acids (FFAs). Macrophages were incubated with conditioned medium from lipid-laden hepatocytes with or without the PPAR-γ agonist. Wild-type C57BL/6J mice were fed a high-fat diet and administered rosiglitazone.

***Research results***

Primary hepatocytes exhibited significant lipid deposition and increased ROS production after incubation with FFAs. Conditioned medium from lipid-laden hepatocytes promoted macrophage polarization to the M1 type and activation of the TLR4/NF-κB pathway. A PPAR-γ agonist ameliorated oxidative stress and NLRP3 inflammasome activation in lipid-laden hepatocytes and subsequently prevented M1 macrophage polarization. Hepatocyte-specific PPAR-γ deficiency aggravated oxidative stress and NLRP3 inflammasome activation in lipid-laden hepatocytes, which further promoted M1 macrophage polarization. Rosiglitazone administration improved oxidative stress and NLRP3 inflammasome activation in HF diet-induced NAFLD mice in vivo.

***Research conclusions***

Upregulation of PPAR-γ activity alleviated NAFLD through modulation of the crosstalk between hepatocytes and macrophages *via* the ROS-NLRP3-IL-1β signaling pathway.

***Research perspectives***

To elaborate the underlying pathogenesis of NAFLD from the perspective of inflammation and immune activation.

**REFERENCES**

1 **Friedman SL**, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. *Nat Med* 2018; **24**: 908-922 [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9]

2 **Younossi Z**, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nat Rev Gastroenterol Hepatol* 2018; **15**: 11-20 [PMID: 28930295 DOI: 10.1038/nrgastro.2017.109]

3 **Rinella ME**, Sanyal AJ. Management of NAFLD: a stage-based approach. *Nat Rev Gastroenterol Hepatol* 2016; **13**: 196-205 [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3]

4 **Romero-Gómez M**, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. *J Hepatol* 2017; **67**: 829-846 [PMID: 28545937 DOI: 10.1016/j.jhep.2017.05.016]

5 **Buzzetti E**, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). *Metabolism* 2016; **65**: 1038-1048 [PMID: 26823198 DOI: 10.1016/j.metabol.2015.12.012]

6 **Day CP**, James OF. Steatohepatitis: a tale of two "hits"? *Gastroenterology* 1998; **114**: 842-845 [PMID: 9547102]

7 **Younossi ZM**. Non-alcoholic fatty liver disease - A global public health perspective. *J Hepatol* 2019; **70**: 531-544 [PMID: 30414863 DOI: 10.1016/j.jhep.2018.10.033]

8 **Abdelmalek MF**. Nonalcoholic fatty liver disease: another leap forward. *Nat Rev Gastroenterol Hepatol* 2021; **18**: 85-86 [PMID: 33420415 DOI: 10.1038/s41575-020-00406-0]

9 **Lebeaupin C**, Vallée D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. *J Hepatol* 2018; **69**: 927-947 [PMID: 29940269 DOI: 10.1016/j.jhep.2018.06.008]

10 **Marra F**, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. *J Hepatol* 2018; **68**: 280-295 [PMID: 29154964 DOI: 10.1016/j.jhep.2017.11.014]

11 **Sui YH**, Luo WJ, Xu QY, Hua J. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation. *World J Gastroenterol* 2016; **22**: 2533-2544 [PMID: 26937141 DOI: 10.3748/wjg.v22.i8.2533]

12 **Kazankov K**, Jørgensen SMD, Thomsen KL, Møller HJ, Vilstrup H, George J, Schuppan D, Grønbæk H. The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 145-159 [PMID: 30482910 DOI: 10.1038/s41575-018-0082-x]

13 **Tacke F**. Targeting hepatic macrophages to treat liver diseases. *J Hepatol* 2017; **66**: 1300-1312 [PMID: 28267621 DOI: 10.1016/j.jhep.2017.02.026]

14 **Murray PJ**. Macrophage Polarization. *Annu Rev Physiol* 2017; **79**: 541-566 [PMID: 27813830 DOI: 10.1146/annurev-physiol-022516-034339]

15 **Gordon S**, Martinez FO. Alternative activation of macrophages: mechanism and functions. *Immunity* 2010; **32**: 593-604 [PMID: 20510870 DOI: 10.1016/j.immuni.2010.05.007]

16 **Wesolowski SR**, Kasmi KC, Jonscher KR, Friedman JE. Developmental origins of NAFLD: a womb with a clue. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 81-96 [PMID: 27780972 DOI: 10.1038/nrgastro.2016.160]

17 **Luo W**, Xu Q, Wang Q, Wu H, Hua J. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. *Sci Rep* 2017; **7**: 44612 [PMID: 28300213 DOI: 10.1038/srep44612]

18 **Obara N**, Fukushima K, Ueno Y, Wakui Y, Kimura O, Tamai K, Kakazu E, Inoue J, Kondo Y, Ogawa N, Sato K, Tsuduki T, Ishida K, Shimosegawa T. Possible involvement and the mechanisms of excess trans-fatty acid consumption in severe NAFLD in mice. *J Hepatol* 2010; **53**: 326-334 [PMID: 20462650 DOI: 10.1016/j.jhep.2010.02.029]

19 **Li R**, Zhou R, Wang H, Li W, Pan M, Yao X, Zhan W, Yang S, Xu L, Ding Y, Zhao L. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. *Cell Death Differ* 2019; **26**: 2447-2463 [PMID: 30850734 DOI: 10.1038/s41418-019-0312-y]

20 **Ahmadian M**, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPARγ signaling and metabolism: the good, the bad and the future. *Nat Med* 2013; **19**: 557-566 [PMID: 23652116 DOI: 10.1038/nm.3159]

21 **Nakajima A**, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. *Gastroenterology* 2001; **120**: 460-469 [PMID: 11159886]

22 **Hussein OE**, Hozayen WG, Bin-Jumah MN, Germoush MO, Abd El-Twab SM, Mahmoud AM. Chicoric acid prevents methotrexate hepatotoxicity *via* attenuation of oxidative stress and inflammation and up-regulation of PPARγ and Nrf2/HO-1 signaling. *Environ Sci Pollut Res Int* 2020; **27**: 20725-20735 [PMID: 32246423 DOI: 10.1007/s11356-020-08557-y]

23 **Ni XX**, Li XY, Wang Q, Hua J. Regulation of peroxisome proliferator-activated receptor-gamma activity affects the hepatic stellate cell activation and the progression of NASH *via* TGF-β1/Smad signaling pathway. *J Physiol Biochem* 2021; **77**: 35-45 [PMID: 33188625 DOI: 10.1007/s13105-020-00777-7]

24 **Severgnini M**, Sherman J, Sehgal A, Jayaprakash NK, Aubin J, Wang G, Zhang L, Peng CG, Yucius K, Butler J, Fitzgerald K. A rapid two-step method for isolation of functional primary mouse hepatocytes: cell characterization and asialoglycoprotein receptor based assay development. *Cytotechnology* 2012; **64**: 187-195 [PMID: 22105762 DOI: 10.1007/s10616-011-9407-0]

25 **Gómez-Lechón MJ**, Donato MT, Martínez-Romero A, Jiménez N, Castell JV, O'Connor JE. A human hepatocellular *in vitro* model to investigate steatosis. *Chem Biol Interact* 2007; **165**: 106-116 [PMID: 17188672]

26 **Biswas SK**, Chittezhath M, Shalova IN, Lim JY. Macrophage polarization and plasticity in health and disease. *Immunol Res* 2012; **53**: 11-24 [PMID: 22418728 DOI: 10.1007/s12026-012-8291-9]

27 **Gross B**, Pawlak M, Lefebvre P, Staels B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. *Nat Rev Endocrinol* 2017; **13**: 36-49 [PMID: 27636730 DOI: 10.1038/nrendo.2016.135]

28 **Schuppan D**, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. *J Hepatol* 2018; **68**: 238-250 [PMID: 29154966 DOI: 10.1016/j.jhep.2017.11.012]

29 **Orr JS**, Puglisi MJ, Ellacott KL, Lumeng CN, Wasserman DH, Hasty AH. Toll-like receptor 4 deficiency promotes the alternative activation of adipose tissue macrophages. *Diabetes* 2012; **61**: 2718-2727 [PMID: 22751700 DOI: 10.2337/db11-1595]

30 **Wu HM**, Ni XX, Xu QY, Wang Q, Li XY, Hua J. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism *via* a Toll-like receptor 4/NF-κB signaling pathway. *J Gastroenterol Hepatol* 2020; **35**: 1998-2008 [PMID: 32128893 DOI: 10.1111/jgh.15025]

31 **Tosello-Trampont AC**, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. *J Biol Chem* 2012; **287**: 40161-40172 [PMID: 23066023 DOI: 10.1074/jbc.M112.417014]

32 **Stienstra R**, Saudale F, Duval C, Keshtkar S, Groener JE, van Rooijen N, Staels B, Kersten S, Müller M. Kupffer cells promote hepatic steatosis *via* interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. *Hepatology* 2010; **51**: 511-522 [PMID: 20054868 DOI: 10.1002/hep.23337]

33 **Huang W**, Metlakunta A, Dedousis N, Zhang P, Sipula I, Dube JJ, Scott DK, O'Doherty RM. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. *Diabetes* 2010; **59**: 347-357 [PMID: 19934001 DOI: 10.2337/db09-0016]

34 **Ricote M**, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature* 1998; **391**: 79-82 [PMID: 9422508]

35 **Feng X**, Yu W, Li X, Zhou F, Zhang W, Shen Q, Li J, Zhang C, Shen P. Apigenin, a modulator of PPARγ, attenuates HFD-induced NAFLD by regulating hepatocyte lipid metabolism and oxidative stress *via* Nrf2 activation. *Biochem Pharmacol* 2017; **136**: 136-149 [PMID: 28414138 DOI: 10.1016/j.bcp.2017.04.014]

36 **Morán-Salvador E**, Titos E, Rius B, González-Périz A, García-Alonso V, López-Vicario C, Miquel R, Barak Y, Arroyo V, Clària J. Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells. *J Hepatol* 2013; **59**: 1045-1053 [PMID: 23831119 DOI: 10.1016/j.jhep.2013.06.023]

37 **Yang CC**, Wu CH, Lin TC, Cheng YN, Chang CS, Lee KT, Tsai PJ, Tsai YS. Inhibitory effect of PPARγ on NLRP3 inflammasome activation. *Theranostics* 2021; **11**: 2424-2441 [PMID: 33500734 DOI: 10.7150/thno.46873]

38 **Wang W**, Xu MJ, Cai Y, Zhou Z, Cao H, Mukhopadhyay P, Pacher P, Zheng S, Gonzalez FJ, Gao B. Inflammation is independent of steatosis in a murine model of steatohepatitis. *Hepatology* 2017; **66**: 108-123 [PMID: 28220523 DOI: 10.1002/hep.29129]

39 **Lee SM**, Pusec CM, Norris GH, De Jesus A, Diaz-Ruiz A, Muratalla J, Sarmento-Cabral A, Guzman G, Layden BT, Cordoba-Chacon J. Hepatocyte-Specific Loss of PPARγ Protects Mice From NASH and Increases the Therapeutic Effects of Rosiglitazone in the Liver. *Cell Mol Gastroenterol Hepatol* 2021; **11**: 1291-1311 [PMID: 33444819 DOI: 10.1016/j.jcmgh.2021.01.003]

40 **Grasselli E**, Voci A, Canesi L, De Matteis R, Goglia F, Cioffi F, Fugassa E, Gallo G, Vergani L. Direct effects of iodothyronines on excess fat storage in rat hepatocytes. *J Hepatol* 2011; **54**: 1230-1236 [PMID: 21145833 DOI: 10.1016/j.jhep.2010.09.027]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Ethics Committee of Renji Hospital.

**Institutional animal care and use committee statement:** All animal experiments fulfilled the Shanghai Jiao Tong University criteria for the humane treatment of laboratory animals and were approved by the Renji Hospital Animal Care and Use Committee (Permit number: RJ2018-0930). All methods were carried out in accordance with relevant guidelines and regulations.

**Conflict-of-interest statement:** All authors have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**ARRIVE guidelines statement:** The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work noncommercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 26, 2022

**First decision:** May 1, 2022

**Article in press:** June 22, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C, C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Boscá L, Spain; Kulkeaw K, Thailand **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Cai YX


**Figure Legends**




**Figure 1 Lipid-laden primary hepatocytes have direct effects on macrophage M1/M2 polarization and inflammation.** Primary hepatocytes were incubated with free fatty acids for 24 h to induce the nonalcoholic fatty liver disease hepatocyte model. Cell culture supernatants of hepatocytes were collected and prepared for different conditioned mediums (CMs). RAW264.7 macrophages were treated with different CMs for 6 h for RT–PCR or 24 h for western blotting. A: Primary hepatocytes isolated by in situ perfusion of collagenase (inverted microscope, × 200, × 400); B: Lipid accumulation in hepatocytes measured by Oil Red O staining (× 400); C: Triglyceride and total cholesterol contents in primary hepatocytes; D: mRNA expression of lipid-related genes in primary hepatocytes; E: mRNA expression of M1/M2 markers in macrophages treated with CM; F: Protein expression of the TLR4/NF-κB pathway in macrophages treated with CM. Values are expressed as the mean ± SE of the mean, *aP* < 0.05, *bP* < 0.01 *vs* normal control (NC) or CM-NC, *n* = 3 experiments. NC: Normal control; CM: Conditioned medium; Fasn: Fatty acid synthase; Srebp1c: Sterol-regulatory element-binding protein 1C; Acox1: Acyl-CoA oxidase 1; Cpt1a: Carnitine palmitoyltransferase 1A; Nos: Nitric oxide synthase; Tnf: Tumor necrosis factor; Il: Interleukin; Arg1: Arginine-1; Mrc2: Mannose receptor 2; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor kappa-B; IκBα: Inhibitor of nuclear factor kappa-B.




**Figure 2 Lipid-laden hepatocytes induce macrophage M1 polarization and inflammation *via* IL-1β signaling.** Primary hepatocytes were incubated with free fatty acids for 6 h for RT–PCR or 24 h for western blot and ELISA. Cell culture supernatants of hepatocytes were collected and prepared for different conditioned mediums (CMs). RAW264.7 macrophages were pretreated with interleukin-1 receptor antagonist and treated with different CMs for 6 h for RT–PCR or 24 h for western blotting. A: mRNA expression of Il-1β in primary hepatocytes; B: Protein expression of IL-1β in primary hepatocytes; C: IL-1β production in the hepatocyte culture supernatant; D: mRNA expression of Il-1β in macrophages; E: mRNA expression of M1/M2 markers in macrophages; F: Protein expression of the TLR4/NF-κB pathway in macrophages. Values are expressed as the mean ± SE of the mean, *aP* < 0.05, *bP* < 0.01 *vs* normal control (NC) or CM-NC; *cP* < 0.05,*dP* < 0.01 comparison of the designated two groups, *n* = 3 experiments. NC: Normal control; CM: Conditioned medium; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; IL-1Ra: Interleukin-1 receptor antagonist; Nos: Nitric oxide synthase; Tnf: Tumor necrosis factor; Il: Interleukin; Arg1: Arginine-1; Mrc2: Mannose receptor 2; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor kappa-B; IκBα: Inhibitor of nuclear factor kappa-B.




**Figure 3 Upregulating PPAR-γ activity ameliorates oxidative stress and NLRP3 inflammasome activation in lipid-laden hepatocytes.** Primary hepatocytes were preincubated with the PPAR-γ agonist GW1929 for 3 h, followed by treatment with free fatty acids for 6 h for RT–PCR or 24 h for western blot and reactive oxygen species (ROS) detection. A: ROS production in primary hepatocytes; B: IL-1β production in the hepatocyte culture supernatant; C: mRNA expression of NLRP3 inflammasome-related genes in hepatocytes; D: Protein expression of NLRP3 inflammasome-related genes in hepatocytes; E: mRNA expression of Ppar-γ and oxidative stress-related genes in hepatocytes; F: Protein expression of oxidative stress-related genes in hepatocytes. Values are expressed as the mean ± SE of the mean, *aP* < 0.05, *bP* < 0.01 *vs* normal control;*cP* < 0.05, *dP* < 0.01 comparison of the designated two groups, *n* = 3 experiments. NC: Normal control; ROS: Reactive oxygen species; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; IL: Interleukin; Keap1: Kelch-like ECH-associated protein 1; Nrf2: NF-E2-related factor 2; Ho-1: Heme oxygenase-1; Nlrp3: NLR family pyrin domain-containing 3; Caspase-1: Cysteinyl aspartate-specific proteinase-1; Ppar-γ: Peroxisome proliferators-activated receptor-γ.



**Figure 4 Hepatocyte-specific PPAR-γ knockout aggravates oxidative stress and NLRP3 inflammasome activation in lipid-laden hepatocytes.** Primary hepatocytes were isolated from PPAR-γfl/fl and PPAR-γ▲hep mice and treated with free fatty acids for 6 h for RT–PCR or 24 h for western blot, ELISA and reactive oxygen species (ROS) detection. A: mRNA expression of Ppar-γ in PPAR-γ-deficient hepatocytes; B: IL-1β production in PPAR-γ-deficient hepatocyte culture supernatant; C: ROS production in PPAR-γ deficiency hepatocytes; D: mRNA expression of NLRP3 inflammasome-related genes in PPAR-γ-deficient hepatocytes; E: Protein expression of NLRP3 inflammasome-related genes in PPAR-γ-deficient hepatocytes; F: mRNA expression of oxidative stress-related genes in PPAR-γ-deficient hepatocytes; G: Protein expression of oxidative stress-related genes in PPAR-γ-deficient hepatocytes. Values are expressed as the mean ± SE of the mean, *aP* < 0.05, *bP* < 0.01 *vs* ppar-γfl/fl or normal control-ppar-γfl/fl;*cP* < 0.05, *dP* < 0.01 comparison of the designated two groups, *n* = 3 experiments. NC: Normal control; ROS: Reactive oxygen species; GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; Keap1: Kelch-like ECH-associated protein 1; Nrf2: NF-E2-related factor 2; Ho-1: Heme oxygenase-1; Nlrp3: NLR family pyrin domain-containing 3; Caspase-1: Cysteinyl aspartate-specific proteinase-1; Ppar-γ: Peroxisome proliferators-activated receptor-γ; IL: Interleukin.



**Figure 5 Regulation of PPAR-γ activity in lipid-laden hepatocytes affects macrophage polarization and inflammation.** Primary hepatocytes were preincubated with the PPAR-γ agonist GW1929 for 3 h, followed by treatment with free fatty acids (FFAs) for 24 h (GW1929+FFA). Primary hepatocytes were isolated from PPAR-γfl/fl and PPAR-γ▲hep mice and treated with FFA for 24 h. Cell culture supernatants of hepatocytes were collected and prepared for different conditioned mediums (CMs). Macrophages were treated with different CMs for 6 h for RT–PCR or 24 h for western blotting. A: mRNA expression of M1/M2 markers in macrophages treated with CM; B: Protein expression of the TLR4/NF-κB pathway in macrophages treated with CM; C: mRNA expression of M1/M2 markers in macrophages treated with CM from PPAR-γ knockout hepatocytes; D: Protein expression of the TLR4/NF-κB pathway in macrophages treated with CM from PPAR-γ knockout hepatocytes. Values are expressed as the mean ± SE of the mean, *aP* < 0.05, *bP* < 0.01 *vs* CM- normal control (NC) or CM-NC-ppar-γfl/fl; *cP* < 0.05, *dP* < 0.01 comparison of the designated two groups, *n* = 3 experiments. NC: Normal control; CM: Conditioned medium; Nos: Nitric oxide synthase; Tnf: Tumor necrosis factor; Il: Interleukin; Arg1: Arginine-1; Mrc2: Mannose receptor 2; TLR4: Toll-like receptor 4; NF-κB: Nuclear factor kappa-B; IκBα: Inhibitor of nuclear factor kappa-B.



**Figure 6 Rosiglitazone improved NLRP3 inflammasome activation and oxidative stress in high-fat diet-induced nonalcoholic fatty liver disease mice.** Wild-type C57BL/6 mice were fed either an normal control diet or an high-fat diet for 16 wk. Rosiglitazone was administered by oral gavage once daily for 28 consecutive days after 12 wk of HF diet feeding. A: mRNA expression of NLRP3 inflammasome-related genes in the bulk cells of liver; B: mRNA expression of Ppar-γ and oxidative stress-related genes in the liver; C: IL-1β Level in the plasma; D: Caspase-1 activity in the liver; E: SOD activity and GSH content in the plasma; F: ROS and MDA production in the plasma. Values are expressed as the mean ± SE of the mean, *aP* < 0.05, *bP* < 0.01 *vs* NC; *cP* < 0.05, *dP* < 0.01 comparison of the designated two groups, *n* = 10 animals per group. HF: High-fat; NC: Normal control; RSG: Rosiglitazone; Keap1: Kelch-like ECH-associated protein 1; Nrf2: NF-E2-related factor 2; Ho-1: Heme oxygenase-1; Nlrp3: NLR family pyrin domain-containing 3; Caspase-1: Cysteinyl aspartate-specific proteinase-1; Ppar-γ: Peroxisome proliferators-activated receptor-γ; IL: Interleukin; SOD: Superoxide dismutase; GSH: Glutathione; MDA: Malondialdehyde; ROS: Reactive oxygen species.

**Table 1 Murine primers**

|  |  |  |
| --- | --- | --- |
| **Primer** | **Forward (5′-3′)** | **Reverse (5′-3′)** |
| Nos2 | GTGTTCCACCAGGAGATGTTG | CTCCTGCCCACTGAGTTCGTC |
| Tnf | TCTTCTCATTCCTGCTTGTGG | GGTCTGGGCCATAGAACTGA |
| Il-6 | GTTCTCTGGGAAATCGTGGA | GGAAATTGGGGTAGGAAGGA |
| Arg1 | CTCCAAGCCAAAGTCCTTAGAG | AGGAGCTGTCATTAGGGACATC |
| Mrc2 | TACAGCTCCACGCTATGGATT | CACTCTCCCAGTTGAGGTACT |
| Il-10 | GTTACTTGGGTTGCCAAG | TTGATCATCATGTATGCTTC |
| Acox1 | ACCAGCCCAACTGTGACTTC | ACAAAGGCATGTAACCCGTA |
| Cpt1a | CTTCCCATTTGACACCTTTG | ATACGTGAGGCAGAACTTGC |
| Srebp1c | ACAGCAACCAGAAGCTCAAG | TGCCCTCCATAGACACATCT |
| Fasn | TTGGGTGCTGACTACAACCT | TGGATGATGTTGATGATGGA |
| Keap1 | AGAGCGGGATGAGTGGCA | GCTGAATTAAGGCGGTTTGTC |
| Nrf2 | CTTTAGTCAGCGACAGAAGGAC | AGGCATCTTGTTTGGGAATGTG |
| Ho-1 | AGACCGCCTTCCTGCTCAACAT | TCTGACGAAGTGACGCCATCTGT |
| Nlrp3 | GAGTTCTTCGCTGCTATGT | ACCTTCACGTCTCGGTTC |
| Caspase-1 | TGGAGAGAAACAAGGAG | TTGAAGAGCAGAAAGCAAT |
| Il-1β | TCTTTGAAGTTGACGGACCC | TGAGTGATACTGCCTGCCTG |
| Ppar-γ | GCCCTTTACCACAGTTGATTTCT | GTGATTTGTCCGTTGTCTTTCCT |
| β-actin | TGTTACCAACTGGGACGACA | CTGGGTCATCTTTTCACGGT |

Acox1: Acyl-CoA oxidase 1; Arg1: Arginine-1; Caspase-1: Cysteinyl aspartate-specific proteinase-1; Cpt1a: Carnitine palmitoyltransferase 1A; Fasn: Fatty acid synthase; Ho-1: Heme oxygenase-1; Il: Interleukin; Nos: Nitric oxide synthase; Keap1: Kelch-like ECH-associated protein 1; Mrc2: Mannose receptor 2; Nlrp3: NLR family pyrin domain-containing 3; Nrf2: NF-E2-related factor 2; Ppar-γ: Peroxisome proliferators-activated receptor-γ; Srebp1c: Sterol-regulatory element-binding protein 1C; Tnf: Tumor necrosis factor.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**